Sunday, September 24, 2023
Clinical Advances in Systemic Lupus Erythematosus:
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse clinical presentations, providing assessment and management challenges to patients and physicians. While therapeutic advances have led to improvements in patient outcomes and survival in the past few decades, mortality and treatment adverse effects remain relatively high. Patient-clinician interaction is an integral part of managing SLE. Effective communication leads to improved care as symptoms, medications, and other aspects of the disease are addressed. This page provides education on the assessment, management, and treatment of SLE.
Developed through a partnership between Medscape and the Lupus Foundation of America with an independent educational grant from GlaxoSmithKline
Learn about management strategies for optimizing care in patients with SLE.
Download
Steering Committee Chair
Professor of Medicine
Director
Hopkins Lupus Center
Johns Hopkins University
Baltimore, Maryland
Chief, Division of Rheumatology
Northwell Health
Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York
Professor of Medicine
Allegheny Health Network
Temple University School of Medicine
Pittsburgh, Pennsylvania
Director of Clinical Projects
Arthritis & Clinical Immunology Program
Oklahoma Medical Research Foundation
OMRF Professor of Medicine
Department of Rheumatology and Immunology
Adjunct Professor, School of Pharmacy
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Professor of Medicine
Cedars-Sinai Medical Center
David Geffen School of Medicine
University of California, Los Angeles
Associate Director, Rheumatology Fellowship Program
Board of Governors
Cedars-Sinai Medical Center
Los Angeles, California
Professor
University of Pennsylvania
Philadelphia, Pennsylvania
Steering Committee Chair
has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Ablynx; Astellas Pharma, Inc.; EMD Serono, Inc.; Exagen Diagnostics, Inc.; GlaxoSmithKline; Inova Diagnostics; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Exagen Diagnostics, Inc.; Lilly
Owns stock, stock options, or bonds from: Merck & Co., Inc.; Pfizer Inc.
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; BiogenIdec; Bristol-Myers Squibb Company
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; BiogenIdec; Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; GlaxoSmithKline; Mallinckrodt Pharmaceuticals; MedImmune Inc.; Sanofi; Takeda Pharmaceuticals North America, Inc.; UCB Pharma, Inc.
Other: Investigator for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; BiogenIdec; Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Pharmaceuticals; Celgene Corporation; Eli Lilly and Company; EMD Serono, Inc.; GlaxoSmithKline; Kezar Life Sciences; Mallinckrodt Pharmaceuticals; MedImmune Inc.; Nektar Therapeutics; Sanofi; Takeda Pharmaceuticals North America, Inc.; UCB Pharma, Inc.;
Has disclosed the following relevant financial relationships:
Other: Co-Investigator for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Site Principal Investigator for: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Merck & Co., Inc.; Serono
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Anthera Pharmaceuticals; Boston Pharmaceuticals; Bristol-Myers Squibb Company; Celgene Corporation; EMD Serono, Inc.; Exagen Diagnostics, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals; Lilly; MedImmune Inc.; Neovacs; Pfizer Inc.; Questcor Pharmaceuticals, Inc.; RemeGen; Sanofi; Takeda Pharmaceuticals North America, Inc.; UCB Pharma, Inc.; Xencor, Inc.;
Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; EMD Serono, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals; Lilly; UCB Pharma, Inc.;
Received grants for clinical research from: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; EMD Serono, Inc.; Exagen Diagnostics, Inc.; Genentech, Inc.; GlaxoSmithKline; Lilly; MedImmune Inc.; Neovacs; Pfizer Inc.; UCB Pharma, Inc.; Xencor, Inc.;
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: EMD Serono, Inc.; Lilly; Pfizer Inc.; Glennark Pharmaceuticals
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ACI; Amgen Inc.; Biogen; Biostrategies; Bristol-Myers Squibb Company; BSL Behring; Celgene Corporation; EMD Serono, Inc.; Gilead Sciences, Inc.; Genentech, Inc.; Idera; Immune Pharmaceuticals; Incyte Corporation; Janssen Pharmaceuticals; Lilly; MedImmune Inc.; Nektar Therapeutics; Neovcs; Octapharma; Pfizer Inc.; Principia; Resolve; Syntimmune;
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Biogen; Celgene Corporation; Corbus Pharmaceuticals; Genentech, Inc.; Janssen Pharmaceuticals; Pfizer Inc.; Syntimmune;
